Spectrum Pharmaceutecals Inc (SPPI)

[antihama]

Regarding your Q on Evomela’s market share potential

Have no idea how he came up with $9M being 35% of melphalan market. All databases I have report only 3 alkylating agents above $100M. These are Bendamustine, Cyclophosphamide, Temodar. Valchlor (i.e. papa mustard in it's newest incarnation) seems to be pushing the $50-$60M mark but all else is below this.

Any references/thoughts

I heard this said before but it was reiterated in the CASI Zach’s article I posted a couple of days ago

The use of captisol technology to reformulate melphalan is anticipated to allow for longer administration durations and slower infusion rates, potentially enabling clinicians to avoid reductions and safely achieve a higher dose intensity of pre-transplant chemotherapy.

So it finally dawned on me that Evomela’s flexibility with “longer administration durations and slower infusion rates” puts Evomela in a good position to be competing, not just in the melphalan generic market, but with other myeloablative therapies since it seems you can pick from an assortment of myeloablative drugs to achieve the outcome you want. Below is a reference to various Myeloablative treatments used in patients for transplantation in multiple myeloma. You get the sense that there is flexibility in what treatment doctors can use and I see this as potentially taking share from other myeloablatives and expanding Evomela’s market. Anyhows, we’ll get another clue in less than a month at the next quarterly meeting.

Myeloablative treatments for multiple myeloma: update of a comparative study of different regimens used in patients from the Spanish registry for transplantation in multiple myeloma.
Leuk Lymphoma. 2002 Jan;43(1):67-74..

This study evaluated outcomes of 4 different conditioning regimen used for autologous SCT in MM:
- MEL200: Melphalan 200 mg/m2 (472 patients)
- MEL140+TBI: - Melphalan 140 mg/m2 + Total Body Irradiation (135 patients)
- BU-MEL: Busulfan 12 mg/Kg + Melphalan 140 mg/m2 (186 patients)
- BU-CY: Busulphan 14 mg/Kg + Cyclophosphamide 120 mg/Kg (28 patients)

There were no significant differences between the 4 conditioning regimens, in terms of hematological recovery and transplant-related mortality. Response rate was 100% with BU-MEL and 86-93% in the other groups (p<0.05). Differences in event-free survival and overall survival did not reach statistical significance.